Alizyme's R&D costs bring higher than expected losses
This article was originally published in Scrip
Executive Summary
Alizyme's net loss for the first half of this year was significantly higher than expected at £8.9 million, far exceeding Piper Jaffray analysts' forecasts of £3.6 million.